PSYENCE BIOMEDICAL LTD

PBMNASDAQ

🏆 #4072 by market capUS Equity

$3.40▼ $0.13 (−3.68%)

Pre-market · at close

1h—

24h▼ 3.7%

7d▲ 4.6%

14d▲ 13.7%

30d▲ 20.1%

1y▼ 85.2%

🏦Market Cap

$13M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $3.38 – $3.44
52-Week Range: $1.92 – $216.37
Volume: $3.01B
Avg Volume: $3.83B
Shares Outstanding: 3.8M
Next Earnings: Oct 2, 2026

Fundamentals Snapshot

Annual Revenue: $6M
Last Q Revenue: $2M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-98.35
Dividend Yield: —

Why Investors Own PBM

✓High-growth profile — revenue up +30.9% YoY with expanding US Equity exposure.
✓Healthy economics — 33% gross margin and 23% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$6M▲ +30.7% YoY

Gross Margin (TTM)

32.5%▲ +4.2% YoY

Operating Income (TTM)

$1M▲ +30.7% YoY

Free Cash Flow (TTM)

$2M▲ +30.7% YoY

About PSYENCE BIOMEDICAL LTD

Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.

🦦